A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report

Tomohiro Iwasawa1, Takeo Kosaka1*, Shinya Morita1, Shuji Mikami3, Kohei Nakamura2, Hiroshi Hongo1, Hiroshi Nishihara2 and Mototsugu Oya1

Abstract

Background: Abnormalities in homologous recombination contribute to the aggressive nature of castration-resistant prostate cancer. Retinoblastoma transcriptional corepressor 1 (RB1) and breast cancer 2 (BRCA2) exist close to each other in the same chromosome, and the significance of their concurrent loss has become a hot topic in the field of cancer research.

Case presentation: A 61-year-old man presented with a chief complaint of a mass on his head and was diagnosed as multiple bone metastases from prostate cancer. He was treated with standard medication, but he died 2 years 6 months after being diagnosed with prostate cancer. Simultaneous biallelic loss of RB1 and BRCA2 as well as a truncating mutation of tumor protein p53 (TP53) were revealed by genomic analysis.

Conclusion: To our knowledge, this is the first report of castration-resistant prostate cancer (CRPC) with BRCA2 and RB1 co-loss and TP53 mutation. To establish a treatment strategy for highly malignant cases with such multiple genetic features is important.

Keywords: Castration-resistant prostate cancer, Genomic profiling, RB1, BRCA2, TP53

Background

Prostate cancer is the most common type of cancer among men in the United States, and its prevalence is increasing in Japan [1]. The standard treatment for advanced prostate cancer is androgen deprivation therapy (ADT), but various mechanisms result in resistance to this therapy, leading to castration-resistant prostate cancer (CRPC). Enzalutamide, abiraterone, and cabazitaxel are currently available as therapeutic agents for metastatic CRPC, and treatment strategies have dramatically changed over time. Abnormalities in homologous recombination (HR) contribute to the aggressive nature of CRPC [2]. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor that has just been approved for use in Japan, was shown to be effective for CRPC with breast cancer 1, breast cancer 2 (BRCA2), or ATM serine/threonine kinase mutations in the PROfound trial [3]. However, the detailed clinicopathological features of CRPC with HR defects are still unclear. Herein, we report on the case of a Japanese patient with CRPC in whom co-loss of retinoblastoma transcriptional corepressor 1 (RB1) and BRCA2 as well as a mutation of tumor protein p53 (TP53) were detected.

*Correspondence: takemduro@gmail.com

1 Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Case presentation
A previous healthy 61-year-old man visited a local doctor with a chief complaint of a mass on his head. He was referred to the neurosurgery department of our hospital on suspicion of a tumor in the skull. Magnetic resonance imaging of the head was performed by 3 T device (GE DISCOVERY MR750; GE Healthcare) with Gadolinium-based contrast agent, and metastatic tumor was suspected (Fig. 1A). Blood examination showed a high prostate-specific antigen level of 165.42 ng/mL, and a computed tomography scan detected lytic lesions of pelvic bone adjacent to the abnormally enlarged prostate. (Fig. 1B). 99mTc-Hydroxymethylene diprophosphate bone scintigraphy revealed multiple bone metastases throughout the body (Fig. 1C). The patient was further referred to our department on suspicion of multiple bone metastases from prostate cancer.

A needle biopsy of the patient’s prostate revealed an adenocarcinoma with a Gleason score of 5 + 4 = 9, which prompted ADT. Elevation of the prostate-specific antigen level and postrenal failure due to urinary retention were observed 1 year after ADT started, and channel transurethral resection of the prostate (TURP) was thus performed. Docetaxel was administered for a total of seven courses because the patient’s tumor was considered to have acquired castration resistance. However, multiple lymph node and bone metastases were exacerbated. Although a total of six courses of cabazitaxel had already been administered, it was discontinued owing to sacral pressure ulcer infection and deterioration of the patient’s general condition. He was subsequently treated with abiraterone, but he died 2 years 6 months after being diagnosed with prostate cancer (Fig. 2).

We performed genetic sequencing of 160 cancer-related genes (PleSSision-Rapid®) using specimens collected by TURP. RB1 and BRCA2 co-deletion as well as a truncating mutation of TP53 (G244Rfs*19) were detected. Amplification of the androgen receptor (AR)
Immunohistochemical staining was performed using standard protocols. The products of the antibodies and the detailed protocols are shown in the additional file. All stained sections were scanned using a high-resolution digital slide scanner (NanoZoomer-XR C12000; Hamamatsu Photonics, Hamamatsu, Shizuoka, Japan), which consisted of a trilinear sensor camera, a detector of 4096 pixels × 64 lines × 3 plates, and a filter that only divides into RGB with a prism. The measured resolution of all microscopy images was 0.23 μm/pixel, which was equivalent to 40 × objective lens.

Hematoxylin and eosin staining showed that tumor cells had clear nucleoli and a histology different from that of typical neuroendocrine prostate cancer cells (Fig. 3). Complete absence of RB1 and p53 protein expressions (Additional file 1: Fig. S1A–B) were consistent with genomic findings. AR was stained in 70% of tumor nuclei and PSA was positive in about 30% of tumor cells (Additional file 1: Fig. S1C–D), whereas neuroendocrine markers were not stained (Additional file 1: Fig. S1E–G).

Immunohistochemical staining of glioma-associated oncogene family zinc finger 1 (GLI1) was performed to confirm whether the hedgehog signal was enhanced by a mutation of PTCH1 in our case. GLI1-positive tumor cells accounted for less than 10% of the total (Additional file 1: Fig. S1H) and the nuclear stainability of the cells was not stronger than that of Leydig cells used as positive control (data not shown), indicating that the hedgehog signal was not enhanced.

**Discussion and conclusions**

The case herein described is characterized by (1) Co-loss of RB1 and BRCA2, (2) TP53 mutation, (3) PTCH1 mutation, and (4) A poorly differentiated AR-positive cancer without neuroendocrine features. Chakraborty et al. [4] demonstrated that concurrent loss of RB1 and BRCA2 leads to resistance to ADT and acquisition of epithelial-mesenchymal transition. Both RB1 and BRCA2 exist in the long arm of chromosome 13; even with a single-copy loss, co-loss of RB1 and BRCA2 is associated with shortened survival and increased genomic mutations. The homodeletion of both genes in our case could have contributed to the aggressive clinical course and treatment resistance observed. In addition, the impaired HR due to the BRCA2 deletion could account for the large fluctuation in gene copy numbers.

The concurrent loss of TP53 and RB1, which are well-known tumor suppressor genes, is one of the genomic features of neuroendocrine prostate cancer [5]. Ku et al. [6] reported that knockdown of TP53 and RB1 in prostate adenocarcinoma caused neuroendocrine differentiation, resulting in decreased AR expression and increased neuroendocrine marker expression. Analysis of the data of the Stand Up To Cancer–Prostate Cancer Foundation Prostate Dream Team [7] using cBioPortal, which is the largest database for metastatic CRPC, revealed that 36 of 429 cases exhibited gene alterations in both TP53 and RB1 but that only 15 cases exhibited neuroendocrine differentiation (Fig. 4). BRCA2 alteration was found only in the non-neuroendocrine group in both TP53 and RB1 altered cases. In our case, both TP53 and RB1 were not stained, but the neuroendocrine markers were negative and AR was positive. The possibility that our patient’s adenocarcinoma was in the process of neuroendocrine differentiation at the time of TURP could not be excluded.

PTCH1 is a major component of hedgehog signaling and regulates the glioma-associated oncogene family of downstream transcription factors, and it is reported to be involved in the development or progression of prostate cancer [8]. In the COSMIC database, of a total of 2803 prostate cancer samples, 52 (1.86%) had PTCH1 mutations. The same PTCH1 R441H mutation detected in our case has been reported in cases of breast cancer and colorectal cancer, but the clinical significance of both cases is unknown [9, 10]. The results of immunohistochemical staining did not show activation of GLI1, a transcription factor downstream of PTCH1, suggesting that the PTCH1 missense mutation seen in our case might have been a passenger mutation.

The National Comprehensive Cancer Network [11] guidelines recommend a platinum-based regimen for only CRPC that presents pathologic neuroendocrine differentiation.
differentiation. However, non-neuroendocrine CRPC cases harboring genetic neuroendocrine prostate cancer features, such as \textit{RB1} loss and \textit{TP53} mutation, could be in the process of neuroendocrine differentiation such that they could have already acquired sensitivity to platinum-based chemotherapy. Corn et al.\cite{12} reported that the combination of carboplatin and cabazitaxel was effective for the aggressive variant prostate cancer molecular signature with defects in at least two of the three tumor suppressor genes, namely, \textit{RB1}, \textit{TP53}, and \textit{PTEN}. In addition, research has shown that sensitivity to platinum-based chemotherapy is higher in CRPC patients with a DNA repair gene aberration, such as breast cancer 1, \textit{BRCA2}, or ATM serine/threonine kinase, than in those without it \cite{13}. These data suggest that platinum-based chemotherapy and PARP inhibitor treatment could be effective in our case. Further analysis is needed to evaluate whether currently available PARP inhibitors would be just as effective in cases with other genetic features.

To our knowledge, this is the first report of CRPC with \textit{BRCA2} and \textit{RB1} co-loss and \textit{TP53} mutation. Because it is unclear whether therapeutic strategies targeting specific genetic changes are effective, to establish a treatment strategy for highly malignant cases with such multiple genetic features by accumulating cases is important.

\textbf{Abbreviations}

\textit{RB1}: Retinoblastoma transcriptional corepressor 1; \textit{BRCA2}: Breast cancer 2; \textit{TP53}: Tumor protein p53; \textit{AR}: Androgen receptor; \textit{PTCH1}: Patched 1; \textit{GLI1}: Glioma-associated oncogene family zinc finger 1; \textit{PARP}: Poly(ADP-ribose) polymerase; \textit{ADT}: Androgen deprivation therapy; \textit{CRPC}: Castration-resistant prostate cancer; \textit{HR}: Homologous recombination; \textit{TURP}: Transurethral resection of the prostate.

\section*{Supplementary Information}

The online version contains supplementary material available at https://doi.org/10.1186/s12920-022-01286-w.

\textbf{Additional file1.} Immunohistochemical staining of transurethral resection samples. (A) Tumor protein p53. (B) Retinoblastoma transcriptional corepressor. (C) Androgen receptor. (D) Prostate-specific antigen. (E) Synaptophysin. (F) Chromogranin A. (G) Cluster of differentiation 56. (H) Glioma-associated oncogene family zinc finger 1. The bars show 100μm.

\section*{Acknowledgements}

We thank Yoko Suzuki, Emmy Yanagida, and Hiroshi Yamada for technical assistance. This work was supported in part by a Grant-in-Aid for Scientific Research (120H03817 to T.K) from the Ministry of Education, Culture, Sports,
Science and Technology of Japan, and by a research grant to T. Kosaka from the Japan Urological Association.

Author contributions
Conception and design of the study: TI, TK, SM1 and MO. Drafting the manuscript and figures: TI, TK, and HH. Collecting data: TI, SM1 and HH. Performing pathological analysis: TI, TK and SM2. Analysis of the genome sequencing: TK, KN and HN. All authors read and approved the final manuscript.

Funding
This work was supported in part by a Grant-in-Aid for Scientific Research (#20H03817 to TK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a research grant to T. Kosaka from the Japan Urological Association. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The genome data generated and analyzed during the current study have been deposited in the Genome Sequence Archive for Human repository under accession code HRA002421. The data are available from the following link: https://ngdc.cncb.ac.cn/gsa-human/browse/HRA002421

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Keio University Hospital (Approval number 20180015).

Consent for publication
Consent for publication has been obtained from the patient and his family in print and electronic form while the patient was alive.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 2 Genomics Unit, Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 3 Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Received: 8 October 2021 Accepted: 10 June 2022
Published online: 20 June 2022

References
1. Suzuki K. Epidemiology of prostate cancer and benign prostatic hyperplasia. Japan Med Assoc J. 2009;52:478–83.
2. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.
3. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.
4. Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer. N Engl J Med. 2020;382:2091–102.
5. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15:271–86. https://doi.org/10.1038/nrurol.2018.22.
6. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich W, et al. Rb1 and Tip53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and androgen resistance. Science. 2017;355:78–83.
7. Abida W, Cyrtu J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;166:11428–36.
8. Gonnissen A, Isbaerta S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci. 2013;14:13979–4007.
9. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.
10. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.
11. National Comprehensive Cancer Network. Prostate cancer (version 1.2022). 2022; Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
12. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol. 2019;20:1432–43.
13. Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, et al. Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without dna repair gene aberrations. JAMA Netw. open. 2020;3:e2021692.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.